


## 1. Participant Flow



## 2. Baseline Characteristics

	Mean (SD) or % (n/N)
Age (years)*	64.1 (13.0)
Female gender	47.9% (875/1827)
Body Mass Index (kg/m <sup>2</sup> )	27.6 (4.7)
Body Mass Index $\geq$ 25 kg/m <sup>2</sup>	70.0% (1127/1610)
Body Mass Index $\geq$ 30 kg/m <sup>2</sup>	26.0% (419/1610)
<u>Comorbidities</u>	
Diabetes	32.7% (443/1354)
Cardiovascular disease	21.9% (296/1354)
Peripheral vascular disease	12.9% (174/1354)
Heart failure	4.8% ( 65/1354)
Renal failure	8.0% (108/1354)
Arrhythmias	13.3% (180/1354)
Dyslipidaemia	61.3% (830/1354)
Other	11.9% (161/1354)
<u>Number of comorbidities</u>	
0	3.4% (46/1354)
1	49.4% (669/1354)
2	31.1% (421/1354)
3	11.2% (152/1354)
4	3.5% (47/1354)
5	1.0% (14/1354)
6	0.2% (3/1354)
7	0.2% (2/1354)

	Mean (SD) or % (n/N)
Years treated with AHD	8.4 (6.3)*
Monotherapy	44.0% (815/1852)
Free combination	28.0% (519/1852)
SPC only	15.6% (289/1852)
Free combination + SPC	11.6% (215/1852)
Two SPCs	0.7% (12/1852)
Free combination + two SPSs	0.1% (2/1852)
'SPC plus'	12.4% (229/1852)
Systolic BP (mmHg)	153.0 (12.4)
Diastolic BP (mmHg)	88.5 (9.4)
Hypertension, grade 1	60.6% (1120/1849)
Hypertension, grade 2	32.5% (601/1849)
Hypertension, grade 3	6.9% (128/1849)
SBP $\geq$ 140 mmHg & DBP $\geq$ 90 mmHg	55.9% (1033/1847)
SBP $\geq$ 140 mmHg & DBP < 90 mmHg	41.1% (758/1847)
SBP < 140 mmHg & DBP $\geq$ 90 mmHg	3.0% (56/1847)
Compliance	
Good	61.9% (862/1393)
Moderate	34.0% (473/1393)
Not	4.2% (58/1393)

### 3. Outcome Measures

	Use of antihypertensive treatment			
	% Monotherapy	% Free combination	% SPC only	% SPC plus
AHD treatment < 5 years	60.6% (284/469)	16.4% (77/469)	16.4% (77/469)	6.6% (31/469)
AHD treatment 5-10 years	47.4% (209/441)	24.5% (108/441)	18.1% (80/441)	10.0% (44/441)
AHD treatment > 10 years	33.0% (218/660)	37.0% (244/660)	12.1% (80/660)	17.9% (118/660)
No comorbidities	60.9% (28/46)	8.7% (4/46)	21.7% (10/46)	8.7% (4/46)
1 or 2 comorbidities	45.1% (492/1090)	27.4% (299/1090)	15.7% (171/1090)	11.7% (128/1090)
≥ 3 comorbidities	17.0% (37/218)	53.2% (116/218)	10.1% (22/218)	19.7% (43/218)
1 AHD pill	73.8% (815/1104)	0.0% (0/1104)	26.2% (289/1104)	0.0% (0/1104)
≥ 2 AHD pills	0.0% (0/748)	69.4% (519/748)	0.0% (0/748)	30.6% (229/748)

	Age	Gender	Years treated with AHD	Compliance
	Mean	% Female	Mean	% Good
Monotherapy	61.2	46.6% (375/804)	6.7	64.6% (390/604)
Free combination	67.5	50.0% (257/514)	10.4	54.1% (206/381)
SPC only	63.4	43.9% (125/285)	7.5	66.8% (151/226)
SPC plus	67.8	52.7% (118/224)	11.0	60.8% (115/182)

	Treatment update, if change indicated %	
	SPC introduced*	SPC changed*
All patients	<b>90.0% (1049/1165)</b>	<b>96.3% (369/383)</b>
Hypertension – Grade 1	90.1% (583/647)	95.2% (198/208)
Hypertension – Grade 2	91.1% (399/438)	98.5% (129/131)
Hypertension – Grade 3	83.5% (66/79)	95.4% (41/43)
AHD treatment < 5 years	88.7% (290/327)	96.6% (85/88)
AHD treatment 5-10 years	91.1% (255/280)	100% (99/99)
AHD treatment > 10 years	91.8% (367/400)	96.2% (125/130)
No comorbidities	75.0% (15/20)	87.5% (7/8)
1 or 2 comorbidities	90.6% (643/710)	97.0% (224/231)
≥ 3 comorbidities	89.1% (114/128)	93.0% (40/43)
1 AHD pill	88.6% (628/709)	96.9% (216/223)
≥ 2 AHD pills	92.3% (421/456)	95.6% (153/160)
Good compliance	86.9% (438/504)	95.7% (179/187)
Moderate or no compliance	92.5% (331/358)	97.5% (115/118)

#### **4. Adverse Events**

There were no adverse events associated with this trial.